Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389519 · ClinicalTrials.gov registry record · Phase 3
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 422
- Enrollment target
NCT00389519 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 422 participants.
The verdict
NCT00389519, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 422 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.
Interventions
- DRUG placebo
- DRUG ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389519
The ClinicalTrials.gov registry entry for NCT00389519 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00389519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389519 about?
NCT00389519 is a clinical study titled "A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents". The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.
What is the current status of trial NCT00389519?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2006-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00389519?
The interventions under investigation include: placebo (DRUG), ramipril (DRUG).
Who is sponsoring clinical trial NCT00389519?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.